Mogling Bio, a Berlin/Ulm, Germany-based biotech company, received a seed funding from Kizoo Technology Capital.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Dr. Jürgen Reess, Mogling Bio develops pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system so that treated cells can perform their tasks again in a juvenile way, and thereby contribute to both, the rejuvenation of stem cells and the immune system.
The underlying technology was developed over the last 15 years by the two scientific co-founders, Prof. Yi Zheng, co-director of the Cincinnati Children’s Hospital Cancer and Blood Diseases Institute and leader of the Signaling and Drug Discovery Program at the Cincinnati Children’s Research Foundation, and Prof. Dr. Hartmut Geiger, director of the Institute of Molecular Medicine at Ulm University in Germany.
FinSMEs
26/10/2022